Regulatory approval risk
Products must obtain and maintain approvals or clearances in each market before sale.
- Scope
- U.S. and foreign markets
- Materiality
- high
ChronoScale Corp
ChronoScale Corp is a U.S.-based medical robotics company focused on robotic exoskeleton systems for rehabilitation and personal mobility. Its business combines device sales, subscription-style financing arrangements, and recurring service offerings such as warranties, repairs, training, and support.
| % | |
|---|---|
| Enterprise Health devices | 55% Robotic exoskeletons used in rehabilitation and clinical treatment settings. |
| Personal Health devices | 20% Exoskeleton products sold for individual mobility and personal use. |
| Subscriptions and financing-linked sales | 10% Device arrangements sold through financing partners or subscription terms. |
| Service and support contracts | 10% Extended warranties, maintenance, repairs, and loaner-device services. |
| Training and clinical support | 5% Product training and clinical onboarding delivered online or in person. |
ChronoScale sells primarily to rehabilitation providers and healthcare organizations that use exoskeletons in clinical...
- Enterprise Health providersprimary
Hospitals, rehabilitation centers, and IDNs buy EksoNR and Ekso Indego Therapy for clinical rehabilitation use.
- Personal Health userssecondary
Individuals and their care networks buy Ekso Indego Personal for mobility and home use.
- Distributorsprimary
Independent distributors buy and market products in non-direct geographies, especially outside German-speaking Europe and Singapore.
- Finance partnerssecondary
Third-party financing partners purchase devices in subscription structures and contract with end customers.
ChronoScale operates across the Americas, EMEA, and APAC, with direct sales used more heavily in the Americas and...
- •Americas are served mainly through a direct salesforce
- •EMEA uses a mix of direct sales and distributors
- •German-speaking Europe is handled directly
- •APAC relies on direct and indirect channels by country
- •Foreign markets require local approvals and distributor compliance
ChronoScale is focused on expanding adoption of its rehabilitation and personal mobility devices through clinical...
01
Expand reimbursement and payer coverageshort-term
Coverage determines affordability and adoption for Personal Health and supports clinical purchasing decisions.
02
Broaden indications of usemedium-term
More approved use cases can increase addressable demand and support product utilization in therapy settings.
03
Commercialize new productsmedium-term
New devices can refresh the portfolio and create incremental revenue streams.
04
Maintain channel reach across regionsshort-term
Distributor and direct-sales coverage are essential for market access outside core geographies.
ChronoScale faces regulatory, reimbursement, and adoption risk because its products are used in healthcare settings and...
Reimbursement and payer coverage risk
Personal Health demand depends on insurance coverage and reimbursement economics.
- Scope
- Personal Health market
- Materiality
- high
Distributor concentration risk
Independent distributors are principal customers in several geographies and can affect access.
- Scope
- Non-German-speaking Europe, EMEA, APAC
- Materiality
- high
Competitive technology risk
Exoskeleton technology is early-stage and competitors can pressure features, pricing, and adoption.
- Scope
- Enterprise Health and Personal Health
- Materiality
- medium
Cybersecurity risk
The business processes sensitive data and relies on connected systems and third-party vendors.
- Scope
- Clinical data and internal systems
- Materiality
- medium
Revenue allocation and recognition
Affects reported revenue timing and mix
Fair value of warrants and preferred stock
Can materially affect net income and equity
Warranty and future service costs
Affects liabilities and gross margin
Inventory valuation
Affects cost of sales and working capital
Deferred tax asset recoverability
Affects tax assets and earnings
: 16/06/2026